NasdaqGS:PGENBiotechs
Can PAPZIMEOS Durability Data Redefine Precigen’s (PGEN) Long-Term Revenue and Immunotherapy Narrative?
In late May 2026, Precigen reported updated long-term follow-up data showing sustained complete responses and no new safety issues for PAPZIMEOS, which had already received full FDA approval and seven-year US market exclusivity as the first and only therapy for adults with recurrent respiratory papillomatosis.
The durability of response, with most complete responders remaining surgery-free for at least three years and some beyond four years, underlines PAPZIMEOS’s role as a new immunotherapy...